Study of Niacin in Glioblastoma

Clinical trial NCT04677049 · SUSPENDED

Trial details

NCT number: NCT04677049
Sponsor: AHS Cancer Control Alberta
Status: SUSPENDED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Start date: 2021-03-18
Primary completion: 2026-12-31
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.